AcuraStem is a patient-based biotechnology company pioneering how treatments are developed for neurodegenerative diseases — including sporadic ALS and FTD — using our proprietary, best-in-class, disease-modeling platform, iNeuroRx®, the gold standard for discovering novel, effective and broadly-acting treatments.
The main reason drugs fail in clinical trials is due to an over reliance on animal models, which leads to a poor understanding of the real human mechanisms driving disease. AcuraStem are leaders and inventors in the generation of individual patient models that accurately recapitulate neurodegenerative disease processes. This, what we call our patient-based approach, leads to more effective treatments, and treatments that can work broadly for patients, not limited to rare, genetically defined subtypes.
learn about our work
Neurodegenerative Disease Areas
Team AcuraStem is honored to continue its partnership with Team Nanci and the ALS Association Golden West Chapter in the fight against ALS as a sponsor of the Greater Los Angeles Walk to Defeat ALS® on Sunday, November 6, at Exposition Park in Los Angeles.
AcuraStem’s Development Candidate AS-202 Demonstrates Excellent Safety and Potency in Preclinical Models Representing Diverse Forms of ALS
AcuraStem (acurastem.com), a patient-based drug discovery platform company developing novel therapeutics for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases, announced the results of extensive preclinical studies on its lead program, AS-202, for ALS patients. The data were presented at the Motor Neuron Disease Association 32nd International Symposium on ALS/MND on December 9, by AcuraStem’s Head of Research, Wen-Hsuan Chang, Ph.D.
Scientific Cofounder, Dr. Justin K. Ichida, and Head of Research, Dr. Wen-Hsuan Chang to present at the 32nd International Symposium on ALS/MND, being held virtually on December 7-10, 2021
AcuraStem will present posters at the 32nd International Symposium on ALS/MND.